Abstract
Background Cognitive impairment associated with lifetime Major Depressive Disorder (MDD) is well-supported by meta-analytic studies, but population-based estimates remain scarce. Previous UK Biobank studies have only shown limited evidence of cognitive differences related to probable MDD. Using updated cognitive and clinical assessments in UK Biobank, this study investigated population-level differences in cognitive functioning associated with lifetime MDD.
Methods Associations between lifetime MDD and cognition (performance on six tasks and general cognitive functioning (g-factor)) were investigated in UK Biobank (N-range 7,457-14,836, age 45-81 years, 52% female), adjusting for demographics, education and lifestyle. Lifetime MDD classifications were based on the Composite International Diagnostic Interview. Within the lifetime MDD group, we additionally investigated relationships between cognition and (i) recurrence, (ii) current symptoms, (iii) severity of psychosocial impairment (while symptomatic), and (iv) concurrent psychotropic medication use.
Results Lifetime MDD was robustly associated with a lower g-factor (β = −0.10, PFDR = 4.7×10−5), with impairments in attention, processing speed and executive functioning (β ≥ 0.06). Clinical characteristics revealed differential profiles of cognitive impairment among case individuals; those who reported severe psychosocial impairment and use of psychotropic medication performed worse on cognitive tests. Severe psychosocial impairment and reasoning showed the strongest association (β = −0.18, PFDR = 7.5×10−5).
Conclusions Findings describe small but robust associations between lifetime MDD and lower cognitive performance within a population based sample. Overall effects were of modest effect size, suggesting limited clinical relevance. However, deficits within specific cognitive domains were more pronounced in relation to clinical characteristics, particularly severe psychosocial impairment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Wellcome Trust (grant number 104036/Z/14/Z) and the Medical Research Council (grant numbers MC_PC_17209, MR/M013111/1, MR/R024065/1). The funders had no role in the design or analysis of this study, decision to publish, or preparation of the manuscript. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Government, British Heart Foundation, Cancer Research UK and Diabetes UK.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
This study used data from UK Biobank, a resource that is available upon registration. The dataset in the form used for the current study may be shared upon request.
